Background: There is a clear association between hyperglycaemia and surgical-site infection (SSI). Intensive glucose control may involve a risk of hypoglycaemia, which in turn results in potentially severe complications. A systematic review was undertaken of studies comparing intensive versus conventional glucose control protocols in relation to reduction of SSI and other outcomes, including hypoglycaemia, mortality and stroke.
Introduction
Surgical-site infection (SSI) causes considerable morbidity and mortality, and increased healthcare costs worldwide 1 . An important factor resulting in an increased risk of SSI is hyperglycaemia; Table 1 gives the definitions used. Multiple mechanisms contribute to hyperglycaemia seen with major surgery. The stress response to operative trauma results in a release of catabolic hormones and inhibition of insulin function. Surgical stress influences pancreatic β cell function, resulting in lower plasma insulin levels. The combination of this relative hypoinsulinaemia, insulin resistance and excessive catabolism due to the action of counter-regulatory hormones commonly leads to hyperglycaemia 2 -4 . Several observational studies 5 -8 on different types of surgery have shown an association between hyperglycaemia and SSI, both in patients with and in those without diabetes. The first large RCT addressing this e96 F. E. E. de Vries, S. L. Gans, J. S. Solomkin, B. Allegranzi, M. Egger, E. P. Dellinger and M. A. Boermeester Table 1 Definitions of terms used
Term Definition
Hyperglycaemia High blood glucose; definitions vary from more than 180 mg/dl (10⋅0 mmol/l) to more than 220 mg/dl (12⋅2 mmol/l) Hypoglycaemia Low blood glucose; definitions vary from less than 40 mg/dl (2⋅2 mmol/l) to less than 80 mg/dl (4⋅4 mmol/l) Conventional protocol
More liberal and higher blood glucose target levels; generally 220 mg/dl (12⋅2 mmol/l) or less Intensive protocol Stricter and lower blood glucose target levels; generally 150 mg/dl (8⋅3 mmol/l) or less Very strict: studies with an upper limit target level of less than 110 mg/dl (6⋅1 mmol/l) Moderately strict: studies with an upper limit target level of 110-150 mg/dl (6⋅1-8⋅3 mmol/l) topic 9 , in 2001, showed a significant reduction in mortality in patients in the ICU when tight glucose control was employed, but conflicting reports have been published since then. In recent years, several systematic reviews and meta-analysis 10 -13 addressing this subject have not all found a clear benefit for intensive versus conventional glucose control protocols when using mortality as an endpoint, and authors have expressed concern regarding the risk of hypoglycaemia and resulting adverse effects.
Recently, additional trials assessing the effect of intensive glucose control have been reported. The aim of the present study was to evaluate the impact of intensive (with stricter and lower blood glucose target levels) versus conventional (with more liberal and higher blood glucose target levels) glucose control protocols on the risk of SSI through a systematic literature review. This review also aimed to define optimal perioperative blood glucose target levels in surgical patients with or without diabetes to prevent SSI. Because of concerns regarding the risk of hypoglycaemia and the potential consequences of hypoglycaemic events, mortality and strokes were included as outcomes in the systematic review and meta-analysis.
Methods
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines 14 were followed.
Search strategy and selection criteria
PubMed, Embase (Ovid), the Cochrane Central Register of Controlled Trials (CENTRAL), the Cumulative Index to Nursing and Allied Health Literature (CINAHL), and WHO global and regional databases were searched for articles published from January 1990 to August 2015, using terms referring to SSI, glucose control and surgical procedures. Studies before 1990 were not included as there have been continual changes in healthcare practices and older studies would confound conclusions. Language was restricted to English, Spanish and French. The complete search is shown in Appendix S1 (supporting information).
Two authors independently screened all titles and abstracts. RCTs comparing a perioperative intensive glucose protocol (with stricter and lower blood glucose target levels) with a conventional glucose protocol (with more liberal and higher blood glucose target levels) in adult patients were included. The primary outcome was SSI (or wound infection). Secondary outcomes were hypoglycaemic events (both laboratory results or clinically relevant), stroke and mortality. Studies comparing different protocols or a different route of administration with comparable blood glucose target levels were excluded. References of the included studies were screened for other relevant studies.
Data extraction
Study characteristics, including year of publication, number of patients, types of surgical procedure, protocols used for glucose control, and outcomes, were retrieved from the text and summarized in an evidence table.
Quality assessment
Quality of the included studies was assessed with the Cochrane Collaboration's tool for assessing risk of bias 15 . The Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology (GRADEpro software 16 ) was used to assess the quality of the body of retrieved evidence.
Statistical analysis
Meta-analyses were performed with Review Manager version 5.3 (The Cochrane Collaboration, The Nordic Cochrane Centre, Copenhagen, Denmark) with a random-effects model. For meta-analyses, studies in the intensive group were divided into studies with a very strict glucose control (upper limit target level less than 110 mg/dl (6⋅1 mmol/l)) and studies with a moderately strict glucose control (upper limit target level 110-150 mg/dl Full-text articles assessed for eligibility n = 27
Total articles included n = 15 
Results
Of the 1839 articles identified by the search, 27 were assessed for full review. A further 12 articles were excluded for the following reasons: five studies 9,17 -20 did not report on SSI or wound infections as a separate outcome; two studies 9, 17 included medical as well as surgical patients; five 21 -25 compared a different protocol or route of administration but with comparable blood glucose target levels; one study 26 involved injured patients but no surgical procedure; and one study 27 was not a randomized trial. Finally, 15 RCTs were included for analysis (Fig. 1) .
Study characteristics
Fifteen RCTs 28 -42 compared an intensive (targeting stricter/lower blood glucose levels) with a conventional protocol (targeting more liberal/higher blood glucose levels). All studies in the intensive group used intravenous insulin administration, whereas three studies 35, 38, 41 in the conventional group employed subcutaneous administration. Some studies used continuous insulin administration, whereas others used intermittent administration. One study 29 used a fixed high dose with 20 per cent dextrose separately ('insulin clamp'). All protocols employed are summarized in 28,29,33 -36,38,39,42 were performed in patients undergoing cardiac surgery, four 31, 32, 40, 41 involved patients having abdominal surgery, one study 37 concerned critically ill surgical patients, and one study 30 involved patients undergoing emergency cerebral aneurysm clipping. Most of the studies were performed in an ICU setting.
No study had SSI or wound infection as the primary outcome, but SSI rates were reported. Most studies had a combined outcome of postoperative complications. The definition of SSI/wound infection also differed between studies. Four studies 28, 34, 36, 42 mentioned only deep/organ space wound infections, one study 29 reported only superficial wound infections, and the other studies either reported on both, or did not clearly describe their definitional criteria. The evidence table with baseline characteristics and outcome is summarized in Table 2 . The risk of bias in the included studies was serious, as many variables were scored as unclear or even high ( Table 3) . Perioperative glucose target levels for reduction of surgical-site infection e99 Intensive versus conventional protocol
Fifteen RCTs compared an intensive with a conventional protocol. The meta-analysis, which included 1442 patients in the intensive group and 1394 in the control group, showed a significant benefit for intensive compared with a conventional protocol in reducing SSI (odds ratio (OR) 0⋅43, 95 per cent c.i. 0⋅29 to 0⋅64; P < 0⋅001) (Fig. 2) .
Meta-analysis of eight studies 28,29,31,32,36,40 -42 with a blood glucose target level of less than 110 mg/dl (6⋅1 mmol/l) in the intensive group showed a significant benefit for an intensive protocol (pooled OR 0⋅50, 0⋅35 to 0⋅73) and seven studies 30,33 -35,37-39 with a blood glucose target level of 110-150 mg/dl (6⋅1-8⋅3 mmol/l) showed similar effects (pooled OR 0⋅27, 0⋅09 to 0⋅78) (Fig. 2) . In meta-regression e100
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0·01
Reference
Intensive protocol
of 196
Upper limit target level < 110 mg/dl Abdelmalak et al. 28 Albacker et al. 29 Cao et al. 31 Cao et al. 32 Gandhi et al. 36 Okabayashi et al. 40 Yuan et al. 41 Zheng et al. 42 Subtotal Heterogeneity: τ 2 = 0·00; χ 2 = 6·39, 7 d.f., P = 0·50; I 2 = 0% Test for overall effect: Z = 3·63, P < 0·001
Upper limit target level 110-150 mg/dl Bilotta et al. 30 Chan et al. 33 Desai et al. 34 Emam et al. 35 Grey and Perdrizet 37 Kirdemir et al. 38 Lazar et al. 39 Subtotal Heterogeneity: τ 2 = 0·66; χ 2 = 8·32, 5 d.f., P = 0·14; I 2 = 40%
Test for overall effect: Z = 2·41, P = 0·02 Total Heterogeneity: τ 2 = 0·10; χ 2 = 15·94, 13 d.f., P = 0·25; I 2 = 18% Test for overall effect: Z = 4·20, P < 0·001
Test for subgroup differences: χ 2 = 1·15, 1 d.f., P = 0·28, I 2 = 13·1% 2 Forest plot of surgical-site infection (SSI) following intensive and conventional protocols for target glucose levels. An inverse-variance random-effects model was used for meta-analysis. Odds ratios are shown with 95 per cent confidence intervals analyses, there was no evidence that the effect of intensive blood glucose control differed between studies including patients with or without diabetes (P = 0⋅590). There was some evidence that the effect was smaller in studies that used intensive blood glucose control during surgery only (OR 0⋅88, 0⋅45 to 1⋅74), compared with studies that used intensive blood glucose control after surgery or both during and after operation (OR 0⋅37, 0⋅25 to 0⋅55; P = 0⋅049 for difference between these ORs). This comparison was similar in studies with very strict and moderately strict glucose control (P = 0⋅328).
Adverse events
Meta-analysis of adverse events showed a higher risk of hypoglycaemic events in intensive versus conventional protocols (OR 5⋅55, 95 per cent c.i. 2⋅58 to 11⋅96) (Fig. S1, supporting information) . These results were similar for studies with very strict (blood glucose less than 110 mg/dl (6⋅1 mmol/l)) (OR 4⋅18, 1⋅79 to 9⋅79) and moderately strict (blood glucose 110-150 mg/dl (6⋅1-8⋅3 mmol/l)) (OR 9⋅87, 1⋅41 to 69⋅20) glucose control. However, four 29, 35, 38, 40 of the 12 studies included in the meta-analysis had no hypoglycaemic events and only five 28, 32, 34, 39, 41 found significantly more asymptomatic hypoglycaemic events when using an intensive protocol, whereas three other studies 31, 36, 42 did not find a significant difference. For three studies 30, 33, 37 , the number of patients with a hypoglycaemic event was not reported, so they were not included in the meta-analysis.
Meta-analyses of postoperative death 28 -34,36-39,41,42 and stroke 28, 29, 36, 38, 39, 41 showed no significant differences Values in parentheses are *percentages and †95 per cent confidence intervals. ‡Overall, there was a high risk for blinding (especially outcome assessors), allocation concealment and incomplete outcome data. §Most included studies investigated patients in an ICU setting, with a mainly cardiac population.
between intensive and conventional protocols (OR 0⋅74 (0⋅45 to 1⋅23) and OR 1⋅37 (0⋅26 to 7⋅20) respectively) ( Figs S2 and S3, supporting information) . Meta-regression showed no evidence of a difference in risk of adverse events between studies with very strict and those with moderately strict protocols of intensive glucose control. The risk was similar for hypoglycaemia (P = 0⋅413), mortality (P = 0⋅484) and stroke (P = 0⋅511). All hypoglycaemic events are summarized in Table S2 (supporting  information) .
Achieved blood glucose level
Targeted blood glucose levels, mean achieved blood glucose levels and SSI are shown in Fig. 3 . Achieved blood glucose levels in the intensive group were lower than those in the conventional group for all studies. Four studies 30, 34, 40, 42 did not report the mean achieved blood glucose level but gave the percentage of measurements within the target level, minimum/maximum blood glucose levels, or mentioned the fact that achieved blood glucose levels were significantly different between the groups. An overview of the different blood glucose target levels, achieved mean blood glucose levels and adverse events is shown in Table S2 (supporting information).
GRADE
Overall evidence was qualified using GRADE methodology ( Table 4) . Low quality of evidence shows that an intensive protocol has significant benefit in reducing SSI compared with a conventional protocol. The level of evidence was downgraded owing to serious risk of bias and indirectness. 
Discussion
This systematic review and meta-analysis demonstrates that intensive protocols with stricter and lower blood glucose target levels are associated with a reduction in the number of SSIs, with an increased risk of hypoglycaemic events but without increased risk of stroke or death. Whereas previous reviews focused only on target levels and SSI, the present review also compared achieved target levels in terms of SSI and adverse events.
Meta-regression analysis showed that the benefit of an intensive protocol over a conventional protocol was consistent in both patients with and those without diabetes, and whether commenced during or after surgery. A benefit of an intensive protocol in reducing SSIs was found both in studies with very strict glucose control (glucose level less than 110 mg/dl (6⋅1 mmol/l)) and studies with moderately strict glucose control (glucose level 110-150 mg/dl (6⋅1-8⋅3 mmol/l)). Moreover, the risk of severe adverse events (hypoglycaemia, death and stroke) was comparable between studies with very strict or moderately strict glucose control in the intensive group.
As several cohort studies, in patients with and those without diabetes, have shown that hyperglycaemia is associated with poorer postoperative outcome, most guidelines 43 -46 give blood glucose target levels between 140 and 200 mg/dl (7⋅8-11⋅1 mmol/l). The risk of hypoglycaemia has led to concerns for targeting lower levels. This is based primarily on results of the Normoglycemia in Intensive Care Evaluation -Survival Using Glucose Algorithm Regulation (NICE-SUGAR) study 17 , which showed increased mortality in the intensive protocol group. The present analysis supports the notion that concerns driven by the results of the NICE-SUGAR trial, which did not include surgical patients, should not delay implementation of stricter and lower blood glucose target levels. The NICE-SUGAR trial was performed in an ICU setting with critically ill patients at higher risk of death, and 21⋅6 per cent of the patients already had sepsis at the time of randomization. In addition, blood glucose target levels in the intensive group of the NICE-SUGAR trial are along the lowest of studies performed on this topic: 81-108 mg/dl (4⋅5-6⋅0 mmol/l). Umpierrez and colleagues 24 showed in the Randomized Study of Basal-Bolus Insulin Therapy in the Inpatient Management of People With Type 2 Diabetes (RABBIT-2) trial, which compared a basal-bolus with a sliding-scale insulin protocol targeting blood glucose levels between 100 and 140 mg/dl (5⋅6-7⋅8 mmol/l) in a general surgical population with type 2 diabetes, that the basal-bolus insulin protocol reduced postoperative complications including wound infection, pneumonia, bacteraemia, and respiratory and acute renal failure (OR 3⋅39, 95 per cent c.i. 1⋅50 to 7⋅65; P = 0⋅003), with a difference in wound infections of borderline significance (P = 0⋅050). No difference in mortality, but a decrease in length of ICU stay, was found, showing that blood glucose target levels between 100 and 140 mg/dl are safe. Another observational study, by Furnary and co-workers 47 on patients having cardiac surgery, revealed that blood glucose target levels lower than 150 mg/dl (8⋅3 mmol/l) reduced SSIs by 66 per cent (P < 0⋅001) and reduced mortality.
In 2009, Kao et al. 11 performed a systematic review and meta-analysis investigating perioperative glycaemic control for the prevention of SSI, and concluded there was insufficient evidence to support intensive glucose control over conventional glucose control. This conflict with the results of the present systematic review can be explained by different inclusion criteria. Moreover, several RCTs have been published since the 2009 review, and these have been included in the present review. Other systematic reviews and meta-analyses 10,12,13 on perioperative glucose control focused on specific patient groups or had different endpoints.
In the present meta-analysis of adverse events, only the study of Gandhi and colleagues 36 showed a significantly higher number of stokes and deaths in the intensive compared with the control group. With closer scrutiny of the achieved blood glucose target levels in the two groups, it was found that achieved blood glucose levels were comparable after a 24-h ICU stay (103 mg/dl (5⋅7 mmol/l) versus 104 mg/dl (5⋅8 mmol/l); P = 0⋅720), although they were significantly lower in the intensive protocol group during surgery and at baseline in the ICU (P < 0⋅001). In addition, these achieved blood glucose levels were among the lowest of those in included studies (Fig. 3) , perhaps accounting for the relatively high number of adverse events. Other studies 48, 49 found a clear dose-response relationship between blood glucose levels and SSI, in favour of lower blood glucose levels.
Five studies 28, 32, 34, 39, 41 reported significantly more hypoglycaemic measurements in the intensive group compared with the control group. Although these events were asymptomatic, with none of the studies reporting clinical consequences, it remains unknown to what extent these hypoglycaemic episodes harm patients in the long term and whether this potential harm outweighs the reduced risk of SSI. A higher OR ratio was found for hypoglycaemic events with moderately strict glucose control (OR 9⋅87, 95 per cent c.i. 1⋅41 to 69⋅20) than with very strict glucose control (OR 4⋅18, 1⋅79 to 9⋅79). This is probably due to the fact that only two studies were included in the meta-analysis of moderately strict groups compared with six in the meta-analysis of very strict groups. Thus, targeting lower Perioperative glucose target levels for reduction of surgical-site infection e103 blood glucose levels with an intensive protocol can be performed safely without the risk of a significant increase in serious adverse events. Blood glucose target levels as low as those used for the NICE-SUGAR trial 17 or the Leuven trial 9 (80-110 mg/dl (4⋅5-6⋅0 mmol/l)) should probably be avoided.
Several limitations should be addressed. Most of the studies used in the present meta-analysis were performed in patients undergoing major cardiac or gastrointestinal surgery, with a substantial proportion of the study population having a postoperative ICU stay. It is not known whether the results can be extrapolated to a more general population, although observational studies 7,50 -53 outside the ICU in non-cardiac surgical patients have shown the same effect. Moreover, the infrastructure required to ensure safe intensive glucose control outside the ICU is a major concern, as this demands skilled staff and is associated with higher workload and increased healthcare costs. However, intensive glucose control during the surgical procedure seems achievable in most settings. The results are most likely influenced primarily by the target or achieved blood glucose level, rather than differences in protocols or route of administration. Some studies 21 -23 comparing subcutaneous with intravenous administration with comparable blood glucose target levels did not show any difference in SSI, whereas others 35,38,41 found a significant difference. Therefore, use of subcutaneous insulin administration outside the operation room or ICU might also reduce the number of SSIs. There was substantial clinical heterogeneity between studies with a wide variety in protocols used, blood glucose target levels and achieved target levels. Moreover, in most studies there was a lack of information on baseline use of medication (for example, antibiotics or anticoagulation) and intraoperative details such as blood loss, which might have influenced baseline risk of SSI and outcome.
Targeting stricter and lower blood glucose levels with an intensive protocol of perioperative glucose control reduces SSI without increasing the risk of death or stroke. Although the optimal target level cannot be derived from published data, the summary data of present systematic review and meta-analysis indicate that target glucose levels of less than 150 mg/dl (below 8⋅3 mmol/l) in the perioperative period can be achieved safely with minimal risk of asymptomatic hypoglycaemic events and with no significant increase in serious adverse events.
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